You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Merck
AstraZeneca
Harvard Business School
McKesson

Last Updated: May 9, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Nimotuzumab

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Nimotuzumab?

Nimotuzumab is an investigational drug.

There have been 82 clinical trials for Nimotuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Carcinoma, Esophageal Neoplasms, and Carcinoma, Squamous Cell. The leading clinical trial sponsors are Biotech Pharmaceutical Co., Ltd., Sun Yat-sen University, and Chinese Academy of Medical Sciences.

There are eighty-six US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Nimotuzumab
TitleSponsorPhase
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung CancerHui BuPhase 2
Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell CarcinomaPeking University Third HospitalN/A
Nimotuzumab in Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in ChildrenBiotech Pharmaceutical Co., Ltd.Phase 2

See all Nimotuzumab clinical trials

Clinical Trial Summary for Nimotuzumab

Top disease conditions for Nimotuzumab
Top clinical trial sponsors for Nimotuzumab

See all Nimotuzumab clinical trials

US Patents for Nimotuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Nimotuzumab   Get Started for $10 Binding molecules specific for HER3 and uses thereof MEDIMMUNE, LLC (Gaithersburg, MD)   Get Started for $10
Nimotuzumab   Get Started for $10 Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Get Started for $10
Nimotuzumab   Get Started for $10 Anti-EGFR activatable antibodies CytomX Therapeutics, Inc. (South San Francisco, CA)   Get Started for $10
Nimotuzumab   Get Started for $10 Substituted urea derivatives and pharmaceutical uses thereof SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Nimotuzumab

Drugname Country Document Number Estimated Expiration Related US Patent
Nimotuzumab Australia AU2012340766 2031-11-23   Get Started for $10
Nimotuzumab Brazil BR112014012539 2031-11-23   Get Started for $10
Nimotuzumab Canada CA2856297 2031-11-23   Get Started for $10
Nimotuzumab China CN104093743 2031-11-23   Get Started for $10
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
Johnson and Johnson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.